NCIt definition : A fully human monoclonal antibody directed against the membrane-bound receptor HER3
(ERBB3) with potential antineoplastic activity. Patritumab binds to and inhibits HER3
activation, which may result in inhibition of HER3-dependent PI3K/Akt signaling and
so inhibition of cellular proliferation and differentiation. HER3, a member of the
epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases, is frequently
overexpressed in solid tumors, including breast, lung, and colorectal tumors of epithelial
origin; it has no active kinase domain itself but is activated through heterodimerization
with other members of the EGFR receptor family that do.;
UNII : 86780VJI1Q;
CAS number : 1262787-83-6; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1262787-83-6
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;